Valion Bio Inc VBIO Stock Analysis
- Nasdaq
- Stock
- Market open · no trades yet today
$0.50 down $0.02, 2.92% at close Nov 5
Last close · Previous close $0.52
- Market cap
- At the Nov 5 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.50down $0.02, 2.92%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.52Nov 4
- Volume112.69KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.64MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.47 to $67.50; now $0.50
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
VBIO trailed the S&P 500 in all 5 periods.
| Period | VBIO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VBIO: down 79.8% S&P 500: down 5.4% | VBIO trailed the S&P 500 by 74.4 percentage points Trailed |
| 3M | VBIO: down 93.1% S&P 500: down 4.5% | VBIO trailed the S&P 500 by 88.6 percentage points Trailed |
| YTD | VBIO: down 98.6% S&P 500: up 8.3% | VBIO trailed the S&P 500 by 106.9 percentage points Trailed |
| 1Y | VBIO: down 99.2% S&P 500: up 9.3% | VBIO trailed the S&P 500 by 108.5 percentage points Trailed |
| Long term | ||
| 3Y | VBIO: down 99.9% S&P 500: up 74.8% −90.0% vs +20.5% a year | VBIO trailed the S&P 500 by 174.7 percentage points Trailed |
$10,000 invested in VBIO a year ago (Nov 5, 2025) would be worth about $81 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $10,934.
VBIO trailed the S&P 500 in all 5 periods.
| Period | VBIO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VBIO: down 79.8% S&P 500: down 5.4% | VBIO trailed the S&P 500 by 74.4 percentage points Trailed |
| 3M | VBIO: down 93.1% S&P 500: down 4.8% | VBIO trailed the S&P 500 by 88.3 percentage points Trailed |
| YTD | VBIO: down 98.6% S&P 500: up 7.5% | VBIO trailed the S&P 500 by 106.1 percentage points Trailed |
| 1Y | VBIO: down 99.2% S&P 500: up 8.2% | VBIO trailed the S&P 500 by 107.4 percentage points Trailed |
| Long term | ||
| 3Y | VBIO: down 99.9% S&P 500: up 68.6% −90.0% vs +19.0% a year | VBIO trailed the S&P 500 by 168.5 percentage points Trailed |
$10,000 invested in VBIO a year ago (Nov 5, 2025) would be worth about $81 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,818.
All-time high
$237,150.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Nov 11, 2021.
Stock splits
3
Latest: 1-for-25 on . Share counts adjust after each split.
All 3 splits
- 1-for-25
- 1-for-17
- 1-for-100
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- −$156.00Kup 67.1%
- Net income
- −$18.75M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $126.00K | −$1.43M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | −$600.00K | −$1.48M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$1.50M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$1.93M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $146.00K | −$2.60M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | −$302.00K | −$2.85M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$6.20M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$7.10M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $1.26M | −$8.49M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $1.84M | −$10.10M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $1.18M | −$8.24M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$5.66M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$8.88M | Paused See the note under the price. |
Margins
- Gross 66.7%
- Operating 10,587.2%
- Net 12,019.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$14.67MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$14.58MLast 12 months
- Capital spending$99.00KLast 12 months
- 9,406.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $53.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $2.48MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$17.41MAs of Jun 30, 2026
- Net debt$14.93MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 1.11As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 4.10As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −199.0%Last 12 months
Over the last 12 months, Valion Bio lost money: its net loss was 199.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −69.1%Last 12 months
Over the last 12 months, Valion Bio’s net loss was 69.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Valion Bio Inc
Valion Bio, Inc. is developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease, and immune dysregulation. The Company's lead candidate, Entolimod for acute radiation syndrome (ARS), has been extensively studied and has demonstrated survival benefits and improved tissue recovery in animal models under the FDA's Animal Rule, which allows the Agency to approve new drugs and biological products based on animal efficacy studies when human clinical trials are unethical or not feasible, such as in the case of internal radioactive contamination. Entolimod is a novel Toll-like receptor 5 (TLR5) agonist that activates NF-κB signaling pathways to protect cells from damage and stimulate immune responses. Entolimod for ARS has received Fast Track and Orphan Drug designations from the FDA. Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist designed for potential broader therapeutic applications, including oncology supportive care. Valion Bio's wholly owned subsidiary, Velocity Bioworks, a contract development and manufacturing organization (CDMO), currently provides biomanufacturing services to Valion, and is working towards providing services to third-party biotech companies in the future.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Texas, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
VBIO news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VBIO stock FAQ
What is VBIO stock’s price today?
Valion Bio (VBIO) traded at $0.50 at the close on , down $0.02 (2.92%) from the previous close of $0.52. Over the past 52 weeks it has traded between $0.47 and $67.50.
Does VBIO pay a dividend?
Valion Bio hasn’t paid a dividend in the last twelve months.
What is VBIO’s 52-week high and low?
Over the past 52 weeks VBIO has traded as low as $0.47 and as high as $67.50. At $0.50 at the close on , it is 99.3% below that high and 6.5% above the low.
What is VBIO’s all-time high?
VBIO’s highest closing price was $237,150.00 on , adjusted for stock splits. At $0.50 at the close on , it is 100.0% below that record.
Has VBIO stock ever split?
Yes, three times: 1-for-100 on ; 1-for-17 on ; 1-for-25 on .
How has VBIO stock performed?
Including dividends and measured to the close on , VBIO has returned −98.6% so far this year and −99.2% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.3% and +9.3%. Past performance doesn’t predict future returns.
What sector and industry is Valion Bio in?
Valion Bio is in the Healthcare sector and the Biotechnology industry, and is headquartered in Texas, USA.
What exchange does VBIO trade on?
Valion Bio trades on the Nasdaq under the ticker symbol VBIO. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.